Imaging secondary neuroendocrine tumours of the liver: comparison of I123 metaiodobenzylguanidine (MIBG) and In111-labelled octreotide (Octreoscan).
Functional imaging of neuroendocrine tumours with Octreoscan and I123-metaiodobenzylguanidine (MIBG) is important for assessment prior to various therapies and assessing response. The two imaging methods have not been directly compared in hepatic neuroendocrine tumours. Patients (n = 18) were studied with both imaging techniques. The sensitivity of Octreoscan was 94%, and that of MIBG 39%. No previously occult primary sites were detected. Concurrent octreotide therapy did not reduce the sensitivity of Octreoscan. Widespread bone metastases were seen in two post-liver-transplant patients using Octreoscan. Octreoscan is a sensitive means of detecting hepatic neuroendocrine tumours, and the more specific technique. MIBG has poor sensitivity, reducing its clinical utility. Therapy with I131-MIBG is likely to be applicable to relatively few patients.
Ramage
J K
JK
Institute of Liver Studies, King's College Hospital, London, UK.
Williams
R
R
Buxton-Thomas
M
M
D019797:3-Iodobenzylguanidine; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D006801:Humans; D007205:Indium Radioisotopes; D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D008113:Liver Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary; D018358:Neuroendocrine Tumors / Q000000981:diagnostic imaging* / Q000556:secondary; D015282:Octreotide; D012680:Sensitivity and Specificity; D015899:Tomography, Emission-Computed, Single-Photon
D007205:Indium Radioisotopes; D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D019797:3-Iodobenzylguanidine; D015282:Octreotide